Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19 is a research paper published in Annals of Internal Medicine (2023). On theSindex it has a DataRank of 0.785. It has been cited 31 times, with 16 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.520
From this paper's citation signal
Citation Network Contribution
0.265
From 15 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 16 citers.
NIAID NIH HHS
Grant: P30 AI045008
NCATS NIH HHS
Grant: UL1 TR001881
NIAID NIH HHS
Grant: UM1 AI068634
NIAID NIH HHS
Grant: UM1 AI069423
NIAID NIH HHS
Grant: UM1 AI069424
NIAID NIH HHS
Grant: UM1 AI069432
NIAID NIH HHS
Grant: UM1 AI069463
NIAID NIH HHS
Grant: UM1 AI069534
NIAID NIH HHS
Grant: U01 AI069424
NCATS NIH HHS
Grant: UL1 TR000124
NIAID NIH HHS
Grant: UM1 AI069481
NIAID NIH HHS
Grant: UM1 AI106701
NIAID NIH HHS
Grant: UM1 AI069419
NIAID NIH HHS
Grant: UM1 AI068636
MeSH Terms